Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 + Adebrelimab in HR+/HER2- Advanced Breast Cancer
NCT06470672Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tizetatug rezetecan, adebrelimab in breast cancer, sponsored by Fudan University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
tizetatug rezetecanadebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06470672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470672.